On June 21, Todd Hagopian recommended Insys Therapeutics (INSY). Since then, the stock has gained nearly 20%. After a stock runs like this, many investors are tempted to sell. However, in situations like this, I’ve found it valuable to know which side of the trade the people with superior track records are on before making any trading decisions.
Todd started his Biotech fund at Marketocracy in March, 2011. His returns have averaged 27.91% since then, which compares nicely to the S&P 500’s 9.03% return over the same period. Over the last five and three year periods, he did better than the top U.S. Equity fund manager. Before taking anyone’s investment advice, you should always check out their track record. Click here to see Todd’s. [Read [email protected]]